Rescue Hearing’s initial gene therapy product will target a genetic mutation known to cause progressive hearing loss which eventually leads to deafness.
Hearing loss affects over 466 million people worldwide, yet there are still no approved therapies to restore lost hearing. By harnessing the power of gene therapy, molecular imaging, and advanced diagnostics, we’re not just treating symptoms—we’re going straight to the source of hearing impairment.
Rescue Hearing Inc. is proud to have signed an exclusive worldwide license agreement with Myrtelle, a pioneer in gene therapy solutions. This partnership, launched in Q3 2022, is set to accelerate the development of next-generation hearing loss treatments.
RHI has assembled a team of visionary, internationally recognized physicians, scientists, and bioengineers who share a common passion for developing therapies for humans suffering from hearing loss. The team is developing therapeutic and diagnostic platforms that will address the most difficult hearing loss indications.
Our vision is to eliminate hearing loss as a chronic condition through groundbreaking advancements in gene therapy and medical innovation. We are committed to a future where genetic hearing loss is no longer a lifelong challenge but a treatable condition, giving millions the chance to experience the world of sound.
We are developing a portfolio of precision-engineered gene therapy products including DFNB8 (licensed to Myrtelle) and USH1B/DFNB16 (partnered with MED-EL), leveraging advanced biotechnology and molecular diagnostics to create targeted hearing restoration treatments. Through innovation and expertise, we strive to create targeted treatments that restore hearing and transform lives worldwide.
We are spearheading the development of gene therapy solutions to address the root causes of progressive hearing loss. Our innovative pipeline includes multiple groundbreaking products—with DFNB8 and DFNB16—among them— designed to restore hearing and transform lives.
